Ocuphire Pharma Investor Presentation Deck
13
Summary & Next Steps for Ocuphire Presbyopia Drops
Advance Into Phase 3 with a Differentiated Product Profile
Important Product
Efficacy
Attributes
Safety: Maintain Distance.
Safety: Tolerability
Durability
Fast Onset
Convenient Daily Drops
Tunable Pupil Modulation
Source: VEGA-1 Clinical Study Results
Nyxol+ LDP
Clinical Data
✓
✓
✓
✓
✓
✓
Ocuphire is differentiated by using both the
dilator and sphincter muscles moderately to
reach a pin-hole pupil size
AAO 2021 Presentations
AAO Refractive Surgery Day ePoster
VEGA-1 Presbyopia Presentation by Dr. Jay Pepose
Abstract # 30068457
AAO Retina Day Scientific ePoster
ZETA-1 DR/DME Presentation by Dr. Mike Allingham
Abstract #PO332
Advance into Presbyopia Phase 3
With Registration Trials in 1H22
Towards a Potential NDA Filing in 2023
Ocuphire
PHARMAView entire presentation